Hunter Associates Investment Management LLC continued to hold its stake in Neos Therapeutics, Inc. (NASDAQ:NEOS) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 50,000 shares of the company’s stock at the close of the second quarter. Hunter Associates Investment Management LLC owned 0.22% of Neos Therapeutics worth $365,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. State of Wisconsin Investment Board bought a new position in Neos Therapeutics in the second quarter valued at approximately $102,000. OMERS ADMINISTRATION Corp bought a new position in Neos Therapeutics in the second quarter valued at approximately $110,000. Mission Wealth Management LLC bought a new position in Neos Therapeutics in the first quarter valued at approximately $122,000. Teachers Advisors LLC lifted its stake in Neos Therapeutics by 16.3% in the fourth quarter. Teachers Advisors LLC now owns 25,496 shares of the company’s stock valued at $149,000 after buying an additional 3,572 shares in the last quarter. Finally, Rhumbline Advisers lifted its stake in Neos Therapeutics by 13.6% in the second quarter. Rhumbline Advisers now owns 20,409 shares of the company’s stock valued at $149,000 after buying an additional 2,441 shares in the last quarter. Hedge funds and other institutional investors own 44.29% of the company’s stock.

Neos Therapeutics, Inc. (NASDAQ:NEOS) traded down 1.12% during mid-day trading on Friday, reaching $8.85. 348,738 shares of the company’s stock traded hands. The stock’s market cap is $248.51 million. The company has a 50 day moving average price of $8.88 and a 200-day moving average price of $8.88. Neos Therapeutics, Inc. has a 12 month low of $4.85 and a 12 month high of $9.25.

Neos Therapeutics (NASDAQ:NEOS) last issued its quarterly earnings data on Tuesday, August 8th. The company reported ($0.83) earnings per share for the quarter, meeting the consensus estimate of ($0.83). Neos Therapeutics had a negative return on equity of 611.78% and a negative net margin of 511.74%. The business had revenue of $4.91 million for the quarter. On average, analysts anticipate that Neos Therapeutics, Inc. will post ($3.10) EPS for the current year.

A number of analysts have recently commented on the stock. Cantor Fitzgerald set a $20.00 price objective on shares of Neos Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, August 9th. Zacks Investment Research raised shares of Neos Therapeutics from a “hold” rating to a “buy” rating and set a $9.75 price objective on the stock in a research report on Saturday, June 3rd. BMO Capital Markets reissued an “outperform” rating and issued a $15.00 price objective on shares of Neos Therapeutics in a research report on Tuesday, June 20th. Royal Bank Of Canada set a $12.00 price objective on shares of Neos Therapeutics and gave the stock an “outperform” rating in a research report on Tuesday, August 8th. Finally, ValuEngine raised shares of Neos Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 12th. One analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $13.83.

ILLEGAL ACTIVITY NOTICE: “Hunter Associates Investment Management LLC Holds Holdings in Neos Therapeutics, Inc. (NEOS)” was published by Daily Political and is owned by of Daily Political. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The legal version of this story can be accessed at https://www.dailypolitical.com/2017/09/23/hunter-associates-investment-management-llc-holds-holdings-in-neos-therapeutics-inc-neos.html.

Neos Therapeutics Company Profile

Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).

Want to see what other hedge funds are holding NEOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neos Therapeutics, Inc. (NASDAQ:NEOS).

Institutional Ownership by Quarter for Neos Therapeutics (NASDAQ:NEOS)

Receive News & Ratings for Neos Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.